Literature DB >> 17000222

Withdrawing implantable defibrillator shock therapy in terminally ill patients.

William R Lewis1, Donna L Luebke, Nancy J Johnson, Michael D Harrington, Ottorino Costantini, Mark P Aulisio.   

Abstract

PURPOSE: The purpose of this study is to review a multidisciplinary strategy used to identify patients with terminal illnesses and initiate withdrawal of implantable cardioverter defibrillator (ICD) shock therapy as part of a comprehensive comfort care approach. With indications for ICDs increasing, more patients are receiving devices. Once protected from an arrhythmic death, these patients may develop other terminal diseases such as cancer or congestive heart failure. It is appropriate to withdraw defibrillator shock therapy when such patients desire only comfort care.
METHODS: The charts of ICD patients who had died were reviewed. Two groups emerged: Group 1 (20) included patients whose defibrillator was turned off through the comprehensive comfort care approach. Group 2 (43) included patients whose clinical course was so rapid that the defibrillator was not turned off. Pacing therapy was not withdrawn in either group.
RESULTS: Defibrillator discharges, cause of death, and time from ICD discharge to death were compared. Group 2 patients died more acutely than Group 1. Group 1 experienced fewer shocks prior to death when compared to Group 2. Comparing pacemaker dependent and non-dependent patients, there was no difference in the time between therapy discontinuation and death.
CONCLUSION: This is the largest study to date to review the characteristics of patients with ICDs and terminal illness. Only one-third of terminally ill patients with ICDs were able to have shock therapy withdrawn as part of a comfort care strategy. These patients experienced fewer shocks in the final days of their illness.

Entities:  

Mesh:

Year:  2006        PMID: 17000222     DOI: 10.1016/j.amjmed.2006.01.017

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  16 in total

Review 1.  Informed consent in cardiac resynchronization therapy: what should be said?

Authors:  Daniel B Kramer; Dan W Brock; Usha B Tedrow
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-09

Review 2.  [Treating ICD patients at the end of their lives: attitudes, knowledge, and behavior of doctors and patients. A critical literature analysis].

Authors:  K-H Ladwig; N F Ischinger; J Ronel; C Kolb
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2011-09

3.  Patient expectations from implantable defibrillators to prevent death in heart failure.

Authors:  Garrick C Stewart; Joanne R Weintraub; Parakash P Pratibhu; Marc J Semigran; Janice M Camuso; Kimberly Brooks; Sui W Tsang; Mary Susan Anello; Viviane T Nguyen; Eldrin F Lewis; Anju Nohria; Akshay S Desai; Michael M Givertz; Lynne W Stevenson
Journal:  J Card Fail       Date:  2009-11-04       Impact factor: 5.712

4.  [Dying with/despite a pacemaker].

Authors:  S Reith; U Janssens
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-01-04       Impact factor: 0.840

5.  Adverse experiences with implantable defibrillators in Oregon hospices.

Authors:  Erik K Fromme; Tanya Lugliani Stewart; Margaret Jeppesen; Susan W Tolle
Journal:  Am J Hosp Palliat Care       Date:  2010-11-25       Impact factor: 2.500

6.  Perspectives on withdrawing pacemaker and implantable cardioverter-defibrillator therapies at end of life: results of a survey of medical and legal professionals and patients.

Authors:  Suraj Kapa; Paul S Mueller; David L Hayes; Samuel J Asirvatham
Journal:  Mayo Clin Proc       Date:  2010-09-15       Impact factor: 7.616

Review 7.  Deactivation of pacemakers and implantable cardioverter-defibrillators.

Authors:  Daniel B Kramer; Susan L Mitchell; Dan W Brock
Journal:  Prog Cardiovasc Dis       Date:  2012 Nov-Dec       Impact factor: 8.194

Review 8.  Life-saving devices reach the end of life with heart failure.

Authors:  Daniel D Matlock; Lynne Warner Stevenson
Journal:  Prog Cardiovasc Dis       Date:  2012 Nov-Dec       Impact factor: 8.194

Review 9.  Making decisions about implantable cardioverter-defibrillators from implantation to end of life: an integrative review of patients' perspectives.

Authors:  Krystina B Lewis; Dawn Stacey; Dan D Matlock
Journal:  Patient       Date:  2014       Impact factor: 3.883

10.  Features and outcomes of patients who underwent cardiac device deactivation.

Authors:  Lillian C Buchhalter; Abigale L Ottenberg; Tracy L Webster; Keith M Swetz; David L Hayes; Paul S Mueller
Journal:  JAMA Intern Med       Date:  2014-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.